Published in Biotech Business Week, September 27th, 2004
The $100,000 phase I grant, entitled "Ex vivo venous gene delivery by pulsed electric fields," was awarded through the small business innovative research (SBIR) program and may be followed, upon evaluation, by a phase II award of up to $1 million. Vascular diseases are the number 1 cause of death in the U.S. and other industrialized countries.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.